uPA-targeted oncolytic Sendai virus therapy (DNAVEC)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameuPA-targeted oncolytic Sendai virus therapy (DNAVEC)
Drug Alias NameBioKniferSeV/Fct14dM
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionUrokinase plasminogen activator modulators
TargetsUrokinase plasminogen activator
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesID Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesID Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A